Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha ® (Evolocumab)

Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha First-of-its-Kind Contract Will Demonstrate Value to Harvard Pilgrim Plans for Cardiovascular Patients THOUSAND OAKS, Calif., May 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced from the World Medical Innovation Forum™ focused on cardiovascular disease that Harvard Pilgrim, a health services company providing healthcare coverage for nearly 2.7 million customers in the northeast region of the U.S.,1 has signed an outcomes-based refund contract with Amgen for Repatha® (evolocumab). This first-of-its-kind contract is based on the Repatha cardiovascular outcomes...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news